TY  - BOOK
AU  - Pichard, Augusto D
TI  - Transcatheter versus surgical aortic valve replacement in patients with prior coronary artery bypass graft operation: a PARTNER trial subgroup analysis
SN  - 0003-4975
KW  - *Aortic Valve Stenosis/su [Surgery]
KW  - *Cardiac Catheterization/mt [Methods]
KW  - *Coronary Artery Bypass
KW  - *Coronary Artery Disease/su [Surgery]
KW  - *Heart Valve Prosthesis Implantation/mt [Methods]
KW  - Aged, 80 and over
KW  - Aortic Valve Stenosis/co [Complications]
KW  - Aortic Valve Stenosis/mo [Mortality]
KW  - Coronary Artery Disease/co [Complications]
KW  - Coronary Artery Disease/di [Diagnosis]
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Prospective Studies
KW  - Survival Rate/td [Trends]
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States/ep [Epidemiology]
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
KW  - Randomized Controlled Trial
N1  - Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
N2  - BACKGROUND: The Placement of Aortic Transcatheter Valves (PARTNER) trial reported a reduced rate of mortality in patients with previous coronary bypass grafting (CABG) operation who received surgical aortic valve replacement (SAVR) in comparison with transcatheter aortic valve replacement (TAVR). We sought to further evaluate these groups; CONCLUSIONS: The 2-year follow-up of patients with a history of previous CABG operation in the PARTNER trial demonstrated improved outcomes with SAVR in comparison with TAVR. Further longitudinal assessment is necessary to corroborate these findings and to understand the possible causes. Copyright  2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved; METHODS: We reviewed the database of the 699 patients enrolled in the PARTNER trial. The cohort for this study consisted of 288 patients (41.2%) who had a history of CABG operation before enrollment in the PARTNER trial. All patients were followed up for 2 years; RESULTS: The mean age was 81.5+6.6 years, and 231 patients (80.2%) were men. The preoperative characteristics were similar in 140 patients (48.6%) who received SAVR and 148 (51.4%) who received TAVR. There were no differences between the two groups with respect to the operative outcomes of death, stroke, and myocardial infarction, but the TAVR patients experienced more paravalvular regurgitation (p<0.0001). At 2 years, there was a trend toward greater all-cause mortality in the TAVR patients (hazard ratio [HR] 1.53; 95% confidence interval [CI]: 0.99, 2.35; p=0.052). Furthermore, the TAVR patients had more repeated hospitalization (HR 1.75; 95% CI: 0.99, 3.07; p=0.05), death of any cause or repeated hospitalization (HR 1.52; 95% CI: 1.06, 2.19; p=0.02), and death of any cause or stroke (HR 1.51; 95% CI: 1.00, 2.27; p=0.05)
UR  - http://dx.doi.org/10.1016/j.athoracsur.2014.02.079
ER  -